nach oben

Erschienen in:

01.04.2014 | Original Article

Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease

verfasst von: Anabela Silva-Fernandes, Sara Duarte-Silva, Andreia Neves-Carvalho, Marina Amorim, Carina Soares-Cunha, Pedro Oliveira, Kenneth Thirstrup, Andreia Teixeira-Castro, Patrícia Maciel

Erschienen in: Neurotherapeutics | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disease currently with no treatment. We describe a novel mouse model of MJD which expresses mutant human ataxin-3 at near endogenous levels and manifests MJD-like motor symptoms that appear gradually and progress over time. CMVMJD135 mice show ataxin-3 intranuclear inclusions in the CNS and neurodegenerative changes in key disease regions, such as the pontine and dentate nuclei. Hsp90 inhibition has shown promising outcomes in some neurodegenerative diseases, but nothing is known about its effects in MJD. Chronic treatment of CMVMJD mice with Hsp90 inhibitor 17-DMAG resulted in a delay in the progression of their motor coordination deficits and, at 22 and 24 weeks of age, was able to rescue the uncoordination phenotype to wild-type levels; in parallel, a reduction in neuropathology was observed in treated animals. We observed limited induction of heat-shock proteins with treatment, but found evidence that 17-DMAG may be acting through autophagy, as LC3-II (both at mRNA and protein levels) and beclin-1 were induced in the brain of treated animals. This resulted in decreased levels of the mutant ataxin-3 and reduced intranuclear aggregation of this protein. Our data validate this novel mouse model as a relevant tool for the study of MJD pathogenesis and for pre-clinical studies, and show that Hsp90 inhibition is a promising therapeutic strategy for MJD.

Nur mit Berechtigung zugänglich

Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C et al. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol. 2001;58(11):1821–7.PubMedCrossRef

Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology. 1978;28(7):703–9.PubMedCrossRef

Seidel K, den Dunnen WF, Schultz C, Paulson H, Frank S, de Vos RA et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol. 2010;120(4):449–60.PubMedCentralPubMedCrossRef

Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19(2):333–44.PubMedCrossRef

Huang S, Ling JJ, Yang S, Li XJ, Li S. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain. 2011;134(Pt 7):1943–58.PubMedCentralPubMedCrossRef

Zijlstra MP, Rujano MA, Van Waarde MA, Vis E, Brunt ER, Kampinga HH. Levels of DNAJB family members (HSP40) correlate with disease onset in patients with spinocerebellar ataxia type 3. Eur J Neurosci. 2010;32(5):760–70.PubMedCrossRef

Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci. 1999;19(23):10338–47.PubMed

Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis. 2009;33(3):342–53.PubMedCentralPubMedCrossRef

Yoshida H, Yoshizawa T, Shibasaki F, Shoji S, Kanazawa I. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis. 2002;10(2):88–99.PubMedCrossRef

10.

Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23(4):425–8.PubMedCrossRef

11.

Kaushik S, Cuervo AM. Chaperones in autophagy. Pharmacol Res. 2012;66(6):484–93.PubMedCentralPubMedCrossRef

12.

Lamark T, Johansen T. Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int J Cell Biol. 2012;2012:736905.PubMedCentralPubMedCrossRef

13.

Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94(4):471–80PubMedCrossRef

14.

Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life. 1999;48(4):429–33.PubMedCrossRef

15.

Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet. 2004;13(13):1389–405.PubMedCrossRef

16.

Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet. 2001;10(12):1307–15.PubMedCrossRef

17.

Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem. 2005;280(4):2873–8.

18.

Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaca JL, Dias N et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet. 2011;20(15):2996–3009.PubMedCentralPubMedCrossRef

19.

Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005;11(10):1088–95.PubMedCrossRef

20.

Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet. 2009;18(5):898–910.PubMed

21.

Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA. 2005;102(46):16801–6.PubMedCentralPubMedCrossRef

22.

Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs. 2006;24(6):543–6.PubMedCrossRef

23.

Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol. 2005;56(2):126–37.PubMedCrossRef

24.

Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2002;49(1):7–19.PubMedCrossRef

25.

Chadman KK, Yang M, Crawley JN. Criteria for validating mouse models of psychiatric diseases. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):1–11.PubMedCentralPubMedCrossRef

26.

Costa Mdo C, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol. 2012;97(2):239–57.PubMedCrossRef

27.

Bichelmeier U, Schmidt T, Hubener J, Boy J, Ruttiger L, Habig K et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci. 2007;27(28):7418–28.PubMedCrossRef

28.

Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet. 2002;11(9):1075–94.PubMedCrossRef

29.

Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis. 2008;31(1):89–101.PubMedCrossRef

30.

Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004;24(45):10266–79.PubMedCrossRef

31.

Silva-Fernandes A, Costa Mdo C, Duarte-Silva S, Oliveira P, Botelho CM, Martins L et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis. 2010;40(1):163–76.PubMedCrossRef

32.

33.

Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56(2):115–25.PubMedCrossRef

34.

Curtis HJ. Genetic factors in aging. Adv Genet. 1971;16:305–24.PubMedCrossRef

35.

Palacios C, Martin-Perez R, Lopez-Perez AI, Pandiella A, Lopez-Rivas A. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res. 2010;34(11):1533–8.PubMedCrossRef

36.

Rusmini P, Simonini F, Crippa V, Bolzoni E, Onesto E, Cagnin M et al. 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiol Dis. 2011;41(1):83–95.PubMedCrossRef

37.

Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter-Landsberg C. 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy. PLoS One. 2010;5(1):e8753.PubMedCentralPubMedCrossRef

38.

Harris GM, Dodelzon K, Gong L, Gonzalez-Alegre P, Paulson HL. Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One. 2010;5(10):e13695.PubMedCentralPubMedCrossRef

39.

Rub U, de Vos RA, Brunt ER, Sebesteny T, Schols L, Auburger G et al. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol. 2006;16(3):218–27.PubMedCrossRef

40.

Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2010;37(2):284–93.PubMedCrossRef

41.

Herbst M, Wanker EE. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener Dis. 2007;4(2–3):254–60.PubMedCrossRef

42.

Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest. 2011;121(8):3306–19.PubMedCentralPubMedCrossRef

43.

Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol. 2010;11(8):545–55.PubMedCentralPubMedCrossRef

44.

Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol. 2010;28(9):1520–6.PubMedCentralPubMedCrossRef

45.

Feder JH, Rossi JM, Solomon J, Solomon N, Lindquist S. The consequences of expressing hsp70 in Drosophila cells at normal temperatures. Genes Dev. 1992;6(8):1402–13.PubMedCrossRef

46.

Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 2002;36(1):20–42.PubMedCrossRef

47.

Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 1999;19(8):3248–57.PubMed

48.

Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47–60.PubMedCrossRef

49.

Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. J Neurosci. 2007;27(11):2781–7.PubMedCrossRef

50.

Ferro A, Carvalho AL, Teixeira-Castro A, Almeida C, Tome RJ, Cortes L et al. NEDD8: a new ataxin-3 interactor. Biochim Biophys Acta. 2007;1773(11):1619–27.PubMedCrossRef

51.

Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988;96(5):379–94.PubMedCrossRef

52.

West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231(4):482–97.PubMedCrossRef

53.

Zar JH. Biostatistical Analysis, 4th edn. Prentice Hall, 1999.

Titel: Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease
verfasst von: Anabela Silva-Fernandes
Sara Duarte-Silva
Andreia Neves-Carvalho
Marina Amorim
Carina Soares-Cunha
Pedro Oliveira
Kenneth Thirstrup
Andreia Teixeira-Castro
Patrícia Maciel
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Neurotherapeutics / Ausgabe 2/2014
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-013-0255-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Epilepsy Related to Developmental Tumors and Malformations of Cortical Development

Neuroimaging the Epileptogenic Process

Past and Present Definitions of Epileptogenesis and Its Biomarkers

Molecular Tweezers Targeting Transthyretin Amyloidosis

Mechanisms of Epileptogenesis in Pediatric Epileptic Syndromes: Rasmussen Encephalitis, Infantile Spasms, and Febrile Infection-related Epilepsy Syndrome (FIRES)